Stockreport

Royalty Pharma Reports Third Quarter 2024 Results [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Capital Deployment of approximately $1.2 billion Raising full year 2024 guidance: Portfolio Receipts expected to be $2,750 to $2,800 million NEW YORK, Nov. 06, 2024 [Read more]